Pabatang, Mary Dannica .
HRN: 20-91-37 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/14/2025
CEFUROXIME 750MG (VIAL)
04/14/2025
04/21/2025
IV
330mg
Q8hours
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes